Triazole derivatives as inhibitors of 11-β hydroxysteroid dehydrogenase-1

US8026264B2 · kind B2 · utility

Assignee

• Merck Sharp & Dohme LLC · US

Inventors

• Sherman T. Waddell · Westfield, US
• Gina M. Santorelli · Long Branch, US
• Milana Maletic · Summit, US
• Aaron H. Leeman · Cranford, US
• Xin Gu · Scotch Plains, US
• Donald W. Graham · Mountainside, US
• James M. Balkovec · North Plainfield, US
• Susan D. Aster · Teaneck, US

Key dates

• Filing date: May 26, 2004
• Grant date: Sep 27, 2011
• Expiry date: Oct 25, 2027

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07D487/04
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Triazole derivatives of structural formula I are selective inhibitors of the 11β-hydroxysteroid dehydrogenase-1. The compounds are useful for the treatment of diabetes, such as noninsulin-dependent diabetes (NIDDM), hyperglycemia, obesity, insulin resistance, dyslipidemia, hyperlipidemia, hypertension, Metabolic Syndrome, and other symptoms associated with NIDDM.